Fairmont Chateau Whistler Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2019



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Functional Cures and the Eradication of HIV (X8)


Organizer(s) Lynn Morris, Melanie M. Ott and Kevin V. Morris
March 24—28, 2019
Fairmont Chateau Whistler • Whistler, British Columbia Canada
Discounted Abstract Deadline: Dec 5, 2018
Abstract Deadline: Dec 18, 2018
Scholarship Deadline: Dec 5, 2018
Discounted Registration Deadline: Jan 24, 2019

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation

Sponsored by Gilead Sciences, Inc.

Joint Meeting: HIV Vaccines (X7)

Summary of Meeting:
Human Immunodeficiency Virus type 1 (HIV) causes a persistent infection and results in acquired immunodeficiency syndrome (AIDS). AIDS has remained a global pandemic for over 40 years as HIV integrates into the genome of infected individuals and remains latent for years. Over the last decade, much emphasis has been centered on pathogenesis and vaccine development, but an emerging paradigm is taking place whereby targeted therapeutics are being developed to both control virus expression as well as possibly target viral infected cells for eradication. This conference for the first time brings together an interdisciplinary group of basic and applied scientists working on various aspects of HIV treatment and eradication strategies in an effort to translate our current understanding of HIV biology into meaningful therapeutics and/or eradication of HIV from infected individuals. To accomplish this goal, the conference aims to: 1) Introduce the state of the art in vaccine and neutralizing antibody strategies used to combat HIV; 2) Focus on transcriptional control and modulation of viral latency; and 3) Highlight synthetic biological approaches and genetic therapies currently being developed and clinically validated to combat HIV infection. The conference seeks to bring together an interdisciplinary mix of basic and applied scientists working on functional cures and eradication of HIV in an effort to better understand not only HIV treatment strategies but also the emerging technologies and approaches that will lead to the eventual eradication of HIV from infected individuals.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Sunday, March 24 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 28 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 29 in order to fully experience the meeting.

SUNDAY, MARCH 24

16:00—20:00
Arrival and Registration

Macdonald Foyer
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Macdonald Foyer

MONDAY, MARCH 25

07:00—08:00
Breakfast

Frontenac/Empress
08:00—09:15
Welcome and Keynote Session (Joint)
Meeting has ended...abstracts no longer viewable online.

Macdonald ABCD
* Ann J. Hessell, Oregon Health & Science University, USA

* Sharon R. Lewin, University of Melbourne, Australia

John R. Mascola, NIAID, National Institutes of Health, USA
Challenges and Opportunities for Antibody-Based HIV Vaccines

Robert F. Siliciano, Johns Hopkins University School of Medicine, USA
Understanding Barriers to HIV Cure

09:15—11:15
Antibodies for Prevention, Treatment and Cure (Joint)
Meeting has ended...abstracts no longer viewable online.

Macdonald ABCD
* Sharon R. Lewin, University of Melbourne, Australia

* Ann J. Hessell, Oregon Health & Science University, USA

David D. Ho, Aaron Diamond AIDS Research Center, USA
Engineering Bispecific Antibodies to Prevent/Treat HIV Infection, Quantify Fc-Mediated Effector Functions, Measure Avidity Contribution to Virus Neutralization, and Infer HIV Envelope Spike Density

Coffee Break

Florian Klein, University of Cologne, Germany
Broadly Neutralizing Antibodies for HIV-1 Immunotherapy

Ann Marie Carias, Northwestern University, USA
Short Talk: Distribution and Localization of I.V. injected VRC01 and VRC01-LS in the in vivo Rhesus Macaque Model

Sai Priya Anand, McGill University, Canada
Short Talk: Two Families of Env Antibodies Efficiently Engage Fc-Gamma Receptors and Eliminate HIV-1-Infected Cells

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Frontenac/Empress
13:00—22:00
Poster Viewing

Frontenac/Empress
14:30—16:30
Workshop 1: Immunology of HIV Cure

Macdonald CD
* Leor S. Weinberger, University of California, San Francisco, USA

* Rasmi Thomas, U.S. Military HIV Research Program, USA

James Arthos, NIAID, National Institutes of Health, USA
A Role for MAdCAM and Retinoic Acid in Establishing Viral Replication in Gut-Associated Lymphoid Tissues

Evan Rossignol, Ragon Institute of MGH, MIT, and Harvard, USA
Development of Monoclonal Antibodies from Elite Controllers to Target the HIV Reservoir

Anjie Zhen, University of California, Los Angeles, USA
Checkpoint Inhibitor Dendritic Cell Vaccine Suppresses HIV-1 Replication

David F. G. Malone, University of Oxford, UK
CD56neg NK Cells Have Increased Functional Response to CD16 Stimulation in Chronic HIV

Riddhima Banga, Centre Hospitalier Universitaire Vaudois, Switzerland
PD-1/PD-L1 Interaction Modulates HIV-1 Transcription in Lymph Nodes of Treated Aviremic Individuals

Namita Satija, Icahn School of Medicine at Mount Sinai, USA
A Genetically Encoded Switch to Monitor HIV Infection and Latency within Humanized Mice Reveals HIV-Susceptibility Associated with Diverse T Cell Transcriptional States

Carly G K Ziegler, Massachusetts Institute of Technology, USA
Paired Host-Virus Single Cell Genomics Identifies Cell Types Harboring Virus in Humans and Non-Human Primates

Alexander O. Pasternak, University of Amsterdam, Netherlands
CD32+CD4+ T Cells Are Highly Enriched in HIV DNA


Following Session is for HIV Vaccines (X7)

14:30—16:30
Workshop 1: Lessons from Non-Human Primate Studies

Macdonald AB
* Willy Bogers, Biomedical Primate Research Centre, Netherlands

* Yuxing Li, University of Maryland, USA

Bridget Fisher, Seattle Children's Research Institute, USA
Oral Immunization with Native-Like HIV-1 Trimers Elicits Systemic Immune Responses and Cross-Clade Reactive Anti-V1V2 Antibodies

Miroslaw K. Gorny, New York University School of Medicine, USA
Tight Control of SHIV Challenge in Macaques with Vaccine-Induced Neutralizing and Non-Neutralizing Anti-V2 Antibodies

Paolo Lusso, NIAID, National Institutes of Health, USA
Induction of Cross-Clade Heterologous Tier-2 HIV-1 Neutralizing Antibodies by an mRNA-Based Vaccine in Macaques

Ma Luo, University of Manitoba, Canada
A Vaccine Targeting HIV Maturation Protects Cynomolgus Monkeys Against Vaginal SIVmac251 Acquisition

Mauricio A. Martins, University of Miami, USA
Anti-CTLA-4 Therapy Enhances Vaccine Immunogenicity but not Efficacy Against Simian Immunodeficiency Virus Challenge in Rhesus Macaques

Kimberly M. Cirelli, La Jolla Institute for Immunology, USA
Slow Delivery Immunization Enhances Germinal Center and Neutralizing Antibody Responses via Modulation of Immunodominance

Mario Roederer, NIAID, National Institutes of Health, USA
SIV Escapes from Non-neutralizing Antibodies Blocking α4β7 Integrin Binding

16:30—17:00
Coffee Available

Macdonald Foyer
17:00—19:00
Development of the Innate Cell and Antibody Responses to HIV
Meeting has ended...abstracts no longer viewable online.

Macdonald CD
* Rebecca M. Lynch, George Washington University, USA

* Brian Moldt, Gilead Sciences, Inc., USA

Galit Alter, Ragon Institute of MGH, MIT, and Harvard, USA
Defining Conserved Correlates of Humoral Immune Protection Against SIV/SHIV

Michel C. Nussenzweig, HHMI/Rockefeller University, USA
Targeting B Lymphocytes to Control HIV-1

Mario Roederer, NIAID, National Institutes of Health, USA
Short Talk: SIV Escapes from Non-neutralizing Antibodies Blocking α4β7 Integrin Binding

Jérémy Dufloo, Institut Pasteur, France
Short Talk: Complement Activation at the Surface of HIV-1-Infected Cells

Mariya B. Shapiro, Oregon Health & Science University, USA
Short Talk: Defining the Window of Opportunity for SHIV Clearance with bNAbs in Infant Macaques

Lynn Morris, National Institute for Communicable Diseases, South Africa
Genetic and Structural Features of HIV-1 V2-Specific Antibodies that Mediate ADCC and Block α4β7 Interactions


Following Session is for HIV Vaccines (X7)

17:00—19:00
Clinical Trials for Prevention: Vaccines and Antibodies
Meeting has ended...abstracts no longer viewable online.

Macdonald AB
* Susan W. Barnett, Bill & Melinda Gates Foundation, USA

* Punnee Pitisuttithum, Mahidol University, Thailand

Fatima Laher, University of the Witwatersrand, South Africa
ALVAC-gp120 for Clade C in South Africa

Shelly Krebs, Walter Reed Army Institute of Research, USA
Short Talk: B Cell Priming from RV144 Vaccination Impacts Post-Infection Antibody Responses

Lawrence Corey, Fred Hutchinson Cancer Research Center, USA
Validating Neutralization as a Mechanistic Surrogate of Protection in Passive Antibody Studies

Beatrice Ondondo, Cardiff Metropolitan University, UK
T-Cell Vaccine Trials for HIV

R. Keith Reeves, Harvard Medical School, USA
Short Talk: Human Memory NK Cells Are Potently Induced by HIV and HIV Vaccines

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Frontenac/Empress
19:30—22:00
Poster Session 1

Frontenac/Empress

TUESDAY, MARCH 26

07:00—08:00
Breakfast

Frontenac/Empress
08:00—11:15
Mechanisms of Viral Expression and Control of Host Cell Function
Meeting has ended...abstracts no longer viewable online.

Macdonald CD
* Ya-Chi Ho, Yale School of Medicine, USA

* Mike McCune, Bill & Melinda Gates Foundation, USA

Saba Valadkhan, Case Western Reserve University, USA
An HIV-Induced Mechanism for T Cell Quiescence and Proviral Latency

Eric M. Verdin, Buck Institute For Research On Aging, USA
CRISPR-Based Characterizing of Latency-Associated Pathways

Coffee Break

Jonathan Karn, Case Western Reserve University, USA
Signaling Pathways Controlling HIV Reactivation from Latency

Ivan D'Orso, University of Texas Southwestern Medical Center, USA
Transcriptional Regulatory Mechanisms Shaping HIV Proviral Fate

Joe D. Hiatt, University of California, San Francisco, USA
Short Talk: A Functional Map of HIV-Host Interactions in Primary Human CD4+ T cells

Peter D. Sun, NIAID, National Institutes of Health, USA
Short Talk: Target HIV Viral Release Pathway as A New Antiviral Strategy

Richard E. Sutton, Yale University School of Medicine, USA
Short Talk: Whole Exome Sequencing Identifies SNVs and Indels Associated with HIV+ Elite and Viremic Control


Following Session is for HIV Vaccines (X7)

08:00—11:15
New Technologies for Studying and Inducing B Cells
Meeting has ended...abstracts no longer viewable online.

Macdonald AB
* Ivelin Georgiev, Vanderbilt Vaccine Center, USA

* Andrew B. Ward, The Scripps Research Institute, USA

Gunilla B. Karlsson Hedestam, Karolinska Institutet, Sweden
Antibody Germline Genes and Impact on Vaccine Responses

Steven E. Bosinger, Emory University, USA
In vivo Lineage Tracing of Antigen-Specific B Cells after Vaccination

Ian Setliff, Vanderbilt Vaccine Center, USA
Short Talk: High-Throughput Mapping of B-Cell Receptor Sequence to Antigen Specificity

Coffee Break

James E. Voss, The Scripps Research Institute, USA
Short Talk: Reprogramming the Antigen Specificity of B Cells Using Genome-Editing Technologies

Adrian B. McDermott, National Institutes of Health, USA
Characterization of Antigen-Specific Memory B Cells Following Vaccination

Colin Havenar-Daughton, La Jolla Institute for Immunology, USA
The Antigen-Specific Human Naive B Cell Repertoire: A Starting Point for Vaccine Responses

Kristin L. Boswell, NIAID, National Institutes of Health, USA
Short Talk: Bcl-6/Bcl-xL B Cell Immortalization for Antibody Discovery in Vaccination and Chronic Infection

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Frontenac/Empress

Following Session is for HIV Vaccines (X7)

11:30—13:00
Hands-On Computer Workshop on Los Alamos HIV Sequences Database
Bring your own laptop if you have one
Click here for more information

Macdonald EF
13:00—22:00
Poster Viewing

Frontenac/Empress
16:30—17:00
Coffee Available

Macdonald Foyer
17:00—19:00
Mechanism and Modulation of Latency
Meeting has ended...abstracts no longer viewable online.

Macdonald CD
* George B. Kyei, University of Ghana, Ghana

* Sharon R. Lewin, University of Melbourne, Australia

Melanie M. Ott, University of California, San Francisco, USA
Epigenetic Regulation of HIV Transcription

Monsef Benkirane, Institut de Genetique Humaine, France
HIV-Host Interactions at the Genomic Level

Leor S. Weinberger, University of California, San Francisco, USA
Discovery and Characterization of a Virus-Intrinsic HIV Latency Circuit

Luis M. Agosto, Boston Medical Center, USA
Short Talk: Identification of Novel Pathways that Regulate HIV Transcription using an Unbiased Functional Screen

Leah Plasek, Case Western Reserve University, USA
Short Talk: Investigation of Potential Roles for lncRNAs in Establishment and Maintenance of HIV Latency


Following Session is for HIV Vaccines (X7)

17:00—19:00
Antibody-Virus Coevolution: Vaccines and Lessons from Infection
Meeting has ended...abstracts no longer viewable online.

Macdonald AB
* Daniela Fera, Swarthmore College, USA

Nicole A. Doria-Rose, NIAID, National Institutes of Health, USA
Broadly Neutralizing Antibodies: Lessons from Natural Infection

Kevin O. Saunders, Duke University, USA
Short Talk: CH505 Transmitted/Founder Envelope Elicits Tier 2 Neutralizing Antibodies Against the CD4 Binding and V1V2-Glycan Sites during Human Infection and Macaque Vaccination

Mattia Bonsignori, Duke University, USA
Inference of the VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier

Elise Landais, International AIDS Vaccine Initiative, USA
Fast and Focused Maturation of a VRC01-Class Broadly Neutralizing Antibody Lineage

Marit van Gils, University of Amsterdam, Netherlands
Short Talk: Comparison of Monoclonal Antibodies Induced by BG505 SOSIP Trimer Immunization and BG505 SHIV Infection in Non-Human Primates

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Frontenac/Empress
19:30—22:00
Poster Session 2

Frontenac/Empress

WEDNESDAY, MARCH 27

07:00—08:00
Breakfast

Frontenac/Empress
08:00—11:00
Therapeutic Vaccines and Cure Strategies (Joint)
Meeting has ended...abstracts no longer viewable online.

Macdonald ABCD
* Douglas F. Nixon, Weill Cornell Medicine, USA

* Tomas Hanke, University of Oxford, UK

Jintanat Ananworanich, US Military HIV Research Program, USA
AD26 & MVA Vaccines in Acutely Treated HIV: Safety, Immunogenicity and Viral Rebound

Beatriz Mothe, IrsiCaixa AIDS Research Institute-HIVACAT, Spain
Therapeutic Vaccines after Early ART: Impact on Reservoir

Coffee Break

Warner Craig Greene, Gladstone Institute of Virology and Immunology, USA
Attacking the Latent Reservoir with Convertible CAR-T Cells Programmed with HIV bNAbs

Eric Arts, Western University, Canada
Combining a TLR7 Agonist with a Heterologous Virus-Like Particle for Potent and Specific Latency Reversal in Patient Samples during Stable cART

Daniel Muli Muema, Africa Health Research Institute, South Africa
HIV Infection/FRESH

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Frontenac/Empress

Following Session is for HIV Vaccines (X7)

11:30—13:00
Hands-On Computer Workshop on Los Alamos HIV Immunology Database
Bring your own laptop if you have one
Click here for more information

Macdonald EF
13:00—22:00
Poster Viewing

Frontenac/Empress

Following Session is for HIV Vaccines (X7)

14:30—16:30
Workshop 2: Understanding Antibody and Envelope Structures

Macdonald AB
* Linqi Zhang, Tsinghua University, China

* Alejandro Balazs, Massachusetts General Hospital, USA

Jacqueline Marlene Brady, Harvard Medical School, USA
Isotype-Dependent Protection Against Mucosal HIV Transmission in Humanized Mouse Models

Samantha Marie Townsley, Walter Reed Army Institute of Research, USA
Autoreactivity Mediated by Total IgG Is not Associated with the Development of Neutralization Breadth

Michael B. Zwick, The Scripps Research Institute, USA
An MPER Antibody that Neutralizes HIV Using Recognition Properties and Germline Genes Shared Among Donors

Rory Henderson, Duke University, USA
Antibody Fab Elbow Mutations Modulate Interdomain Flexibility and Dynamics of HIV-1 Broadly Neutralizing Antibodies

Ronnie M. Russell, University of Pennsylvania, USA
Antigenic Conservation of the V2 Apex Among Primate Lentiviruses

Marie Pancera, Fred Hutchinson Cancer Research Center, USA
Structural Basis for Potent Tier 2 Autologous Neutralization Elicited by Vaccination

Andres Finzi, CRCHUM, Université de Montréal, Canada
An Asymmetric Opening of HIV-1 Env Is Required for Anti-Cluster A Antibody Binding

Kimmo Rantalainen, The Scripps Research Institute, USA
Electron Microscopic Characterization of HIV Envelope in Detergent Micelles, Lipid Bicelles and Nanodiscs

16:30—17:00
Coffee Available

Macdonald Foyer
17:00—19:00
Experimental Molecular Approaches to Targeting Viral Reservoirs
Meeting has ended...abstracts no longer viewable online.

Macdonald CD
* Ramesh K. Akkina, Colorado State University, USA

* Paula M. Cannon, University of Southern California, Keck School of Medicine, USA

Romas Geleziunas, Gilead Sciences, Inc., USA
Attacking Latent Reservoirs

Priti Kumar, Yale School of Medicine, USA
Direct in vivo Gene Engineering of Human T Cells for HIV Therapy

Susana T. Valente, Scripps Florida, USA
Silencing the HIV Reservoir

Chantelle L. Ahlenstiel, Kirby Institute, University of New South Wales, Australia
Short Talk: RNA-Directed Epigenetic Silencing Protects Humanized Mice during HIV Challenge

Fabio Romerio, University of Maryland School of Medicine, USA
Short Talk: The HIV-1 Antisense Transcript Ast Induces Viral Latency via Several Silencing Pathways


Following Session is for HIV Vaccines (X7)

17:00—19:00
T Cells in HIV Vaccination and Acute Infection
Meeting has ended...abstracts no longer viewable online.

Macdonald AB
* Barbara L. Shacklett, University of California, Davis, USA

* Diane L. Bolton, US Military HIV Research Program, WRAIR, USA

Christian Brander, Institut de Recerca de la Sida, IrsiCaixa, Spain
Vaccine-Elicited T Cells in Clinical Trials

Stephen A. Migueles, NIAID, National Institutes of Health, USA
Short Talk: Ad5/HIV Vaccines Induce CD8+ T Cells with Insufficient Avidity to Kill HIV-Infected CD4+ T Cells

David B. Masopust, University of Minnesota, USA
Tissue-Resident T Cells

Jonah B. Sacha, Oregon Health & Science University, USA
Unconventional T Cells: Potential for Induction by Vaccination

Leticia Kuri-Cervantes, University of Pennsylvania, USA
Short Talk: Longitudinal Dynamics of Follicular CD4+ T Cells in Acute SIV Infection

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Frontenac/Empress
19:30—22:00
Poster Session 3

Frontenac/Empress

THURSDAY, MARCH 28

07:00—08:00
Breakfast

Frontenac/Empress
08:00—11:15
Targeting and Eradication of HIV
Meeting has ended...abstracts no longer viewable online.

Macdonald CD
* Zabrina L. Brumme, Simon Fraser University, Canada

* Eric M. Verdin, Buck Institute For Research On Aging, USA

David M. Margolis, University of North Carolina at Chapel Hill, USA
Progress Towards Targeting and Eradication of HIV in Models and Man

Sharon R. Lewin, University of Melbourne, Australia
Understanding Natural Variation in HIV Transcription on Antiretroviral Therapy: New Approaches to Reverse HIV Latency

Coffee Break

Deborah Persaud, Johns Hopkins University School of Medicine, USA
Latency and HIV in Pediatric Populations

Lucy Dorrell, University of Oxford, UK
Novel Engineered Immune-Mobilizing T Cell Receptors-Based Drugs (‘ImmTAVs’) to Clear HIV Infection

Bojana Lucic, Universität Heidelberg, Germany
Short Talk: 3D Genome Conformation is the Major Determinant of HIV-1 Integrational Hot-Spots

Alberto Bosque, George Washington University, USA
Short Talk: In vitro, ex vivo and in vivo Analysis of Benzotriazine Derivatives as Latency-Reversing Agents

Marion Pardons, Université de Montréal, CRCHUM, Canada
Short Talk: Latency Reversing Agents Induce Differential Responses in Distinct Memory CD4+ T Cell Subsets


Following Session is for HIV Vaccines (X7)

08:00—11:15
Env Immunogen Design and Evaluation
Meeting has ended...abstracts no longer viewable online.

Macdonald AB
* Ralf Wagner, Universität Regensburg, Germany

* James Mark Binley, San Diego Biomedical Research Institute, USA

Richard T. Wyatt, IAVI Neutralizing Antibody Center, The Scripps Research Institute, USA
NFL Trimers: Down the Rabbit Hole and Other Unlikely Events

David Peterhoff, University Regensburg, Germany
Short Talk: Stabilized HIV-1 Clade C Envelope Trimers with Increased Stability and Preferential Antigenic Properties in vitro and in vivo

Tongqing Zhou, NIAID, National Institutes of Health, USA
Native Glycan Shield Is Important for Inducing Immune Responses that Neutralize Diverse Tier-2 Viruses in Sequential HIV-1 Env Trimer Immunization

Coffee Break

Andrew J. Borst, University of Washington, USA
Short Talk: Germline VRC01 Antibody Recognition of a Modified Clade C HIV-1 Envelope Trimer and a Glycosylated HIV-1 gp120 Core

Karin Loré, Karolinska Institutet, Sweden
In vivo Fate of Env and Early Responses upon Immunization

Derek T. O'Hagan, GlaxoSmithKline Vaccines, USA
Designing and Building the Next Generation of Vaccine Adjuvants

Aleksandar Antanasijevic, The Scripps Research Institute, USA
Short Talk: Development of Self-Assembling Nanoparticle Systems for Presentation of HIV Env Trimers

11:15—17:00
On Own for Lunch

14:30—16:30
Workshop 2: LRA and New Antiviral Strategies

Macdonald CD
* Susana T. Valente, Scripps Florida, USA

* Tristan Alexander Scott, City of Hope, USA

Ya-Chi Ho, Yale School of Medicine, USA
Filgotinib, a Janus Kinase Inhibitor, Suppresses HIV-1 Expression and T Cell Activation

Haitao Hu, University of Texas Medical Branch, USA
A Novel Small Molecule Modulating BRD4 to Epigenetically Suppress HIV

Seohyun Ahn, ST Pharm. Co., Ltd., South Korea
A Highly Potent and Safe Allosteric HIV-1 Integrase Inhibitor: Virological, Molecular and Preclinical Characterization of STP0404

Konstantinos Georgiou, University of California, San Francisco, USA
Single-Cell Sequencing Reveals Transcriptome and Surfaceome Signatures of HIV Latently-Infected Cells

Vera Klemm, Kirby Institute, Australia
Nanoparticle Delivery of Epigenetic Silencing siRNA to the Nucleus of HIV-1-Infected Cells

George B. Kyei, University of Ghana, Ghana
Splicing Factor 3B Subunit 1 Interacts HIV Tat and Can Be Targeted to Prevent Viral Transcription and Reactivation from Latency

Ulf Dittmer, University of Duisburg-Essen, Germany
HIV Cure Strategies with Interferon Alpha Subtype 14 in HIV-1 Infected Humanized Mice

Miriam Rosas-Umbert, AIDS Research Institute Irsicaixa – HIVACAT, Spain
In vivo Effects of Romidepsin in the Bcn02 Kick&Kill Trial for HIV Remission

16:30—17:00
Coffee Available

Macdonald Foyer
17:00—18:45
Protect and Kill Strategies to a Functional Cure
Meeting has ended...abstracts no longer viewable online.

Macdonald CD
* Warner Craig Greene, Gladstone Institute of Virology and Immunology, USA

* Betty Poon, NIAID, National Institutes of Health, USA

Paula M. Cannon, University of Southern California, Keck School of Medicine, USA
Genome Engineering Strategies to Generate HIV-Resistant Cells

Scott G. Kitchen, University of California, Los Angeles AIDS Institute, USA
Engineering Long-Term HIV-Specific Immunity through Chimeric Antigen Receptors and Stem Cells

Kevin V. Morris, Center for Gene Therapy, City of Hope, USA
Flare, Excise, Kill: Means to a Functional Cure for HIV

Chris Peterson, Fred Hutchinson Cancer Research Center, USA
Short Talk: Trafficking of Stem Cell-Derived CAR T-Cells to B-Cell Follicles in SHIV-Infected Nonhuman Primates


Following Session is for HIV Vaccines (X7)

17:00—18:45
From the Lab to the Clinic: A Reality Check for Investigators
Meeting has ended...abstracts no longer viewable online.

Macdonald AB
* Devin Sok, International AIDS Vaccine Initiative, USA

* Silvija I. Staprans, Bill & Melinda Gates Foundation, USA

Mark Connors, NIAID, National Institutes of Health, USA
Impact of Immunogen Design and Replication on Pre-Clinical and Clinical Immunogenicity

Peter D. Kwong, NIAID, National Institutes of Health, USA
Short Talk: Steps Toward a Fusion Peptide-Based Vaccine

Hanneke Schuitemaker, Janssen Vaccines & Prevention B.V., Netherlands
Advancing an HIV Vaccine Candidate through the Development Pipeline: A View from Industry

Antu K. Dey, International AIDS Vaccine Initiative, USA
Translation of Multiple Products from Discovery to the Clinic: The View from a Product Development Center at a Non-Profit Organization

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.

Macdonald CD

Following Session is for HIV Vaccines (X7)

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.

Macdonald AB
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Frontenac/Empress
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Frontenac/Empress

FRIDAY, MARCH 29

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Bill & Melinda Gates Foundation Gilead Sciences, Inc.

We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13AI143392-01

Funding for this conference was made possible (in part) by 1R13AI143392-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Gilead Sciences, Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org,
Phone:+1 970-262-1179